The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Projecting future complications of chronic hepatitis C in the United States
Open accessAbstract
Chronic hepatitis C virus (HCV) infection is common and often results in slowly progressive liver disease. Although acute hepatitis C is now uncommon, most patients with acute infection have developed chronic hepatitis, and, therefore, the pool of infected patients is large. We used a modification of a previously described natural history model for HCV infection to project the number of cases of HCV infection, cirrhosis, and liver failure over the next 40 years. The model estimated the prevalence of HCV infection in the United States was 3.07 × 10 6 in 1993 (compared with an adjusted National Health and Nutrition Evaluation Survey (NHANES) III estimate of 2.8 to 3.5 × 10 6). A gradual decline in the prevalence of infection should occur by year 2040 because of aging and natural deaths among the infected pool. However, as the duration of infection increases in the surviving cohort, the proportion with cirrhosis will increase from 16% to 32% by 2020 in an untreated population. Complications of cirrhosis also will increase dramatically over the next 20 years: hepatic decompensation (up 106%), hepatocellular carcinoma (up 81%), and liver-related deaths (up 180%). Although current treatment regimens eradicate HCV in over 50% of cases, many more patients would need to be treated to significantly impact disease progression. Identification and treatment of every case of HCV infection (with or without cirrhosis) would reduce the number of cases of decompensated cirrhosis by almost half after 20 years. Despite the declining incidence of acute HCV infection, chronic hepatitis C is common. The prevalence of cirrhosis and the incidence of its complications will increase over the next 10 to 20 years, because the duration of infection increases among those with chronic hepatitis C. These data emphasize the need for greater access to transplantation by expansion of the donor pool, increasing use of split livers and living donors, and novel options such as xenotransplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994
Alter, M. J., Kruszon-Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., Kaslow, R. A., & Margolis, H. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908193410802 · Cited by 2,992
Rising Incidence of Hepatocellular Carcinoma in the United States
El-Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,853
(1998) · PsycEXTRA Dataset · doi:10.1037/e547602006-001 · Cited by 1,213
Clinical Outcomes after Transfusion-Associated Hepatitis C
Tong, M. J., El-Farra, N. S., Reikes, A. R., & Co, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506013322202 · Cited by 1,198
Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis
Seeff, L. B., Buskell-Bales, Z., Wright, E. C., Durako, S. J., Alter, H. J., Iber, F. L., Hollinger, F. B., Gitnick, G., Knodell, R. G., Perrillo, R. P., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272703 · Cited by 672
Alter, M. J. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450170079026 · Cited by 615
Estimating future hepatitis C morbidity, mortality, and costs in the United States
(2000) · American Journal of Public Health · doi:10.2105/ajph.90.10.1562 · Cited by 567
Predictors of patient and graft survival following liver transplantation for hepatitis C
Charlton, M., Seaberg, E., Wiesner, R., Everhart, J., Zetterman, R., Lake, J., Detre, K., & Hoofnagle, J. (1998) · Hepatology · doi:10.1002/hep.510280333 · Cited by 537
Darby, S. C., Ewart, D. W., Giangrande, P. L., Spooner, R. J., Rizza, C. R., Dusheiko, G. M., Lee, C. A., Ludlam, C. A., & Preston, F. E. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05413-5 · Cited by 497
Bennett, W. G., Inoue, Y., Beck, J. R., Wong, J. B., Pauker, S. G., & Davis, G. L. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-10-199711150-00001 · Cited by 315
Self-citationMathurin, P., Moussalli, J., Cadranel, J.-F., Thibault, V., Charlotte, F., Dumouchel, P., Cazier, A., Huraux, J.-M., Devergie, B., Vidaud, M., et al. (1998) · Hepatology · doi:10.1002/hep.510270333 · Cited by 302
Poynard, T., McHutchison, J., Davis, G. L., Esteban-Mur, R., Goodman, Z., Bedossa, P., & Albrecht, J. (2000) · Hepatology · doi:10.1053/jhep.2000.19347 · Cited by 280
Self-citationSobesky, R., Mathurin, P., Charlotte, F., Moussalli, J., Olivi, M., Vidaud, M., Ratziu, V., Opolon, P., & Poynard, T. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70135-6 · Cited by 252
THE EPIDEMIOLOGY OF ACUTE AND CHRONIC HEPATITIS C
Alter, M. J. (1997) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70321-4 · Cited by 211
Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C
Barrera, J. M., Bruguera, M., Ercilla, G. M., Gil, C., Celis, R., Gil, P. M., Del Onorato, V. M., Rodés, J., & Ordinas, A. (1995) · Hepatology · doi:10.1002/hep.1840210306 · Cited by 185
Gretch, D. R., Lee, W., & Corey, L. (1992) · Journal of Clinical Microbiology · doi:10.1128/jcm.30.8.2145-2149.1992 · Cited by 112
Muir, A. J., & Provenzale, D. (2002) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200203000-00015 · Cited by 99
Interferon–α in Acute Posttransfusion Hepatitis C:. A Randomized, Controlled Trial
Viladomiu, L., Genescà, J., Esteban, J. I., et al. (1992) · Hepatology · doi:10.1002/hep.1840150504 · Cited by 95
Hepatitis C in State Correctional Facilities
Spaulding, A. C., Greene, C. M., Davidson, K., Schneidermann, M., & Rich, J. D. (1999) · Preventive Medicine · doi:10.1006/pmed.1998.0418 · Cited by 89
Inglesby, T. V., Rai, R., Astemborski, J. A., Gruskin, L., Nelson, K. E., Vlahov, D., & Thomas, D. L. (1999) · Hepatology · doi:10.1002/hep.510290219 · Cited by 88
Addict death rates during a four-year posttreatment follow-up.
Joe, G. W., Lehman, W. E. K., & Simpson, D. D. (1982) · American Journal of Public Health · doi:10.2105/ajph.72.7.703 · Cited by 81
Wong, J. B., Poynard, T., Ling, M.-H., Albrecht, J. K., Pauker, S. G., & on behalf of the International Hepatitis Interventional Therapy (IHIT) Group (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.02089.x · Cited by 79
Takano, S., Satomura, Y., & Omata, M. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90130-9 · Cited by 78
Wong, J. B. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)00881-9 · Cited by 76
Hwang, S., LEE, S., Chan, C.-Y., et al. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(94)80246-7 · Cited by 73
Serfaty, L., Nousbaum, J. B., Elghouzzi, M. H., Giral, P., Legendre, C., & Poupon, R. Y. (1995) · Hepatology · doi:10.1002/hep.1840210319 · Cited by 42
Epidemiology, serological markers, and hepatic disease of anti-HCV ELISA-2-positive blood donors
Salmerón, F. J., Palacios, A., Pérez-Ruiz, M., Torres, C., Oyonarte, S., Fernández-Montoya, A., & Ruiz‐Extremera, A. (1996) · Digestive Diseases and Sciences · doi:10.1007/bf02093592 · Cited by 13
Cited by
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002
Armstrong, G. L., Wasley, A., Simard, E. P., McQuillan, G. M., Kuhnert, W. L., & Alter, M. J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00004 · Cited by 1,955
Assessment of Hepatic Fibrosis With Magnetic Resonance Elastography
Yin, M., Talwalkar, J. A., Glaser, K. J., Manduca, A., Grimm, R. C., Rossman, P. J., Fidler, J. L., & Ehman, R. L. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.06.012 · Cited by 948
Davis, G. L., Alter, M. J., El–Serag, H., Poynard, T., & Jennings, L. W. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.067 · Cited by 878
Self-citationTreating viral hepatitis C: efficacy, side effects, and complications
Manns, M. P., Wedemeyer, H., & Cornberg, M. (2006) · Gut · doi:10.1136/gut.2005.076646 · Cited by 659
Metadata
- Authors
- Davis, G. L., Albright, J. E., Cook, S. F., & Rosenberg, D. M.
- Venue
- Liver Transplantation
- Published
- 2003-04
- Volume
- 9
- Issue
- 4
- Pages
- 331-338
- ISSN
- 1527-6465 (ISSN-L)
- OpenAlex
- W2004360699
- Cited by
- 576
- References
- 29
- FWCI
- 23.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.